



DRUGS & PHARMACEUTICALS LTD.

**MANUFACTURER OF
BULK DRUGS &
IMPORTERS OF
SOLVENTS & CHEMICALS**

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ☎ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ☎ (02525) 271049 Email: info@aareydrugs.com
CIN: L99999MH1990PLC056538

Date:- 15th April, 2024

To,

BSE Limited The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 524412	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: AAREYDRUGS
--	---

Subject: Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended 31st March, 2024.

Dear Sir/Madam,

Please find enclosed herewith Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended 31st March, 2024.

Please take on record of the same and oblige

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Limited

Nimit Rajesh
Ghatalia

Digitally signed by
Nimit Rajesh Ghatalia
Date: 2024.04.15
18:05:38 +05'30'

Nimit Ghatalia
Director
DIN: 07069841

Encl.: a/a

Virendra Bhatt
Practicing Company Secretary

Office:
Office No. 03, A Wing, 9th Floor,
Pinnacle Corporate Park
BKC CST Link Rd., MMRDA Area,
Bandra Kurla Complex,
Bandra East, Mumbai- 400 051,
Maharashtra, India.
Tel.: 022 - 2652 9367 / 68
Mobile No.: +91 98200 48670
Email: bhattvirendra1945@yahoo.co.in

Name of the Company : Aarey Drugs and Pharmaceuticals Limited
CIN : L99999MH1990PLC056538
Registered Office : E-34, M.I.D.C., Tarapur, Boisar, Thane - 401506,
Maharashtra, India.

**CERTIFICATE UNDER REGULATION 40(9) OF THE SEBI (LISTING
OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR
THE FINANCIAL YEAR ENDED 31ST MARCH, 2024**

The Securities and Exchange Board of India (SEBI) vide gazette notification dated 08th June, 2018 and vide its press release dated 03rd December, 2018 ("SEBI's operational guidelines"), amended Regulation 40 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and had mandated transfer of securities only in dematerialized form w.e.f. 01st April, 2019.

Further, the SEBI vide gazette notification dated 24th January, 2022 read with SEBI circular No.: SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022 ("SEBI's operational guidelines") had mandated issuance of certificates or receipts or advices, as applicable in dematerialized form only, while processing the service requests relating to Issue of duplicate securities certificate, Claim from Unclaimed Suspense Account, Renewal / Exchange of securities certificate, Endorsement, Subdivision/Splitting of securities certificate, Consolidation of securities certificates / folios, Transmission and Transposition.

Accordingly, I have examined all the relevant documents relating to **Aarey Drugs and Pharmaceuticals Limited** maintained by **Link Intime India Private Limited ("RTA")** for the purpose of issuing the Certificate as per Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the period from **01st April, 2023 to 31st March, 2024** and based on the information provided, I hereby certify that:



- A. The Company / RTA has delivered / sent during year ended on 31st March, 2024, letters of confirmation as per SEBI's operational guidelines, for execution of transmission and deletion of name, received during the financial year ended 31st March, 2024, within the prescribed time from the respective date of lodgment.
- B. As informed to me, the RTA has not processed any physical transfer, transposition of securities, renewal, consolidation, exchange and sub-division (split) etc. as per SEBI's operational guidelines.

Date: 15th April, 2024

Place: Mumbai

UDIN: A001157F000125578



Virendra G. Bhatt

Practicing Company Secretary

ACS No.: 1157 / COP No.: 124

Peer Review Cert. No.: 1439/2021